omniture

Lotus Pharmaceuticals Announces Update on Land in Inner Mongolia

2010-12-09 21:54 1279

Company to Sell or Transfer Land Parcel to Focus on Core Business


BEIJING, Dec. 9, 2010 /PRNewswire-Asia-FirstCall/ -- Lotus Pharmaceuticals, Inc. (OTC Bulletin Board: LTUS) ("Lotus" or the "Company"), a fast-growing, profitable developer, manufacturer and seller of medicine and drugs in the People's Republic of China ("PRC"), today announced that it plans to sell or transfer approximately 165 acres (1,000 MU) of Company-owned land in the Chahaer Industrial Park, Inner Mongolia.

Lotus' operating entity, Beijing Liang Fang Pharmaceutical Co., Ltd., purchased the land-use rights for the property in 2008. Lotus had originally intended to build a pharmaceutical manufacturing and storage facility on a portion of the property. In March 2010, Lotus began construction on a 250,000-square-foot facility in Beijing after receiving permission from the Beijing Chaoyang District Planning Bureau. The new building will house the Company's R&D center, manufacturing operations, storage facilities, sales and administrative offices. The building will become Lotus' new corporate headquarters following its completion. Management expects to move into the building by June 2011.

Lotus' Chairman and CEO, Mr. Zhongyi Liu, stated, "We have decided not to move forward with the construction of our planned facility in Inner Mongolia in order to focus our efforts and resources on expanding our core business. We believe that selling or transferring this property will be a more effective use of our capital."

About Lotus Pharmaceuticals, Inc.

Lotus Pharmaceuticals, Inc. is a fast-growing, profitable developer and producer of drugs and a licensed national seller of pharmaceutical items in the People's Republic of China (PRC). Lotus operates its business through its two controlled entities: Liang Fang Pharmaceutical, Ltd. and En Ze Jia Shi Pharmaceutical, Ltd. Lotus' current drug development is focused on the treatment of cerebro-cardiovascular diseases, asthma and diabetes. Liang Fang sells drugs directly and indirectly through its national sales channels to hospitals, clinics and drugs stores in 30 provinces of the PRC.

Information Regarding Forward-Looking Statements

Except for historical information contained herein, the statements in this press release are forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which may cause our actual results in future periods to differ materially from forecasted results. These risks and uncertainties include, among other things, product demand, market competition, and risks inherent in our operations. These and other risks are described in our filings with the U.S. Securities and Exchange Commission.

Contacts:




At the Company:


Xing Shen, Ph.D.


VP of Corporate Development


Lotus Pharmaceuticals, Inc.


Tel: +1-415-690-7688


Email: shen@lotuspharma.com


Web: http://www.lotuspharma.com




Investor Relations:


Dave Gentry, U.S.


RedChip Companies, Inc.


Tel: +1-800-733-2447, Ext. 104


Email: info@redchip.com


Web: http://www.redchip.com



Source: Lotus Pharmaceuticals, Inc.
Related Stocks:
OTC:LTUS
collection